BioAge Labs (BIOA) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

BioAge Labs

NasdaqGS•Healthcare•Drug Manufacturers - Specialty & Generic

$9.59+0.09(0.01%)Market closed

Market Cap

$361.40M

P/S

34.9x

P/B

1.0x

BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.

How this company scores

AverageMetricSide Score: 55/100

Strongest: Growth (20/25); weakest: Cash & Earnings Quality (10/25).

Profitability10/25

Growth20/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality10/25

Strengths

Growing revenueInterest easily coveredCash-backed earningsProfit converts from growth

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/S · 34.9x5y range 33.0x – 65.2x

Currently near its 5-quarter median.

P/B · 1.0x5y range 0.2x – 1.8x

Currently above its 8-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $361.40M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $10.36M
Q. Revenue: $2.45M
TTM EBITDA: $-106.02M
TTM Op. Income: $-106.27M
Q. Op. Income: $-29.33M
TTM Net Income: $-94.46M
Q. Net Income: $-26.10M
EPS: $-0.58
Shares Out.: $44.84M

$10.36M in TTM revenue grew 168.1% YoY, reaching $2.45M last quarter. TTM EBITDA of $-106.02M and TTM operating income of $-106.27M show growth is flowing through to the bottom line. However, net income is negative at $94.46M — growth is not yet reaching the bottom line. Across the last 8 quarters, TTM revenue has risen for 5 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: -1193.9%
Op. Margin: -1196.8%
Net Margin: -1064.7%

Op. margin of -1196.8% is down 169.8% YoY — costs are rising relative to revenue. Net margin at -1064.7% Over the past year, operating margin is down 17% — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 34.9x
P/B Ratio: 1.0x

P/S of 34.9x and P/B of 1.0x. P/S is high, meaning growth expectations are priced in.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $396.93M
Cash: $73.96M
Long-Term Debt: N/A
Book Value: $374.91M
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-19.26M
TTM Free Cash Flow: $-88.09M
FCF Margin: -850.7%
FCF / Net Income: 0.9

TTM FCF of $-88.09M on $-19.26M in operating cash flow. The FCF / Net Income ratio of 0.9x means free cash flow covers net income — earnings are backed by cash. Over the past year, free cash flow is up 2% — an improving trend.